Dr. Shore Discusses the Enzalutamide AFFIRM Trial

Neal D. Shore, MD
Published: Friday, Jun 08, 2012

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses findings from the phase III AFFIRM trial that examined the new oral agent enzalutamide (formally MDV3100) for patients with castration-resistant prostate cancer who have failed a prior docetaxel-based chemotherapy.

The trial randomized 1199 patients in a 2:1 ratio to receive either enzalutamide or placebo. The median overall survival benefit for those receiving enzalutamide was 18.4 months compared to 13.6 months in the placebo arm, representing a 4.8-month increase in median overall survival.

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses findings from the phase III AFFIRM trial that examined the new oral agent enzalutamide (formally MDV3100) for patients with castration-resistant prostate cancer who have failed a prior docetaxel-based chemotherapy.

The trial randomized 1199 patients in a 2:1 ratio to receive either enzalutamide or placebo. The median overall survival benefit for those receiving enzalutamide was 18.4 months compared to 13.6 months in the placebo arm, representing a 4.8-month increase in median overall survival.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x